Adverse effects of valproate on bone: Defining a model to investigate the pathophysiology

Epilepsia

Volumn 51, Issue 6, 2010, Pages 984-993

  Senn, Susan M ^a   Kantor, Susan ^a   Poulton, Ingrid J ^a,b   Morris, Margaret J ^c   Sims, Natalie A ^a,b   O'Brien, Terence J ^a   Wark, John D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiepileptic drugs; Bone; Dual energy x ray absorptiometry; Mice; Valproate

Indexed keywords

VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DISEASE; BONE MINERAL; C3H MOUSE; CHRONIC DRUG ADMINISTRATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; STRAIN DIFFERENCE; TRABECULAR BONE;

ANIMALS; BONE DENSITY; BONE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED AKR; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED CBA; MICE, INBRED DBA; SPECIES SPECIFICITY; TIBIA; VALPROIC ACID;

EID: 77954651350     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02516.x     Document Type: Article

References (38)

1. Arroyo S. (2004) Valproate. In Perucca E, Shorvon S, Fish DR, Dodson E (eds) The treatment of epilepsy. Blackwell, Oxford.
2. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. (2004) The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 50:93-97. (Pubitemid 38479673)
3. Borowicz KK, Zadrozniak M, Swiader M, Kowalska A, Kleinrok Z, Czuczwar SJ. (2002) Interaction of the neurosteroid alphaxalone with conventional antiepileptic drugs in different types of experimental seizures. Eur J Pharmacol 449(1-2):85-90.
4. Cho HH, Park HT, Kim YJ, Bae YC, Suh KT, Jung JS. (2005) Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem 96:533-542. (Pubitemid 41504651)
5. El-Khayat HA, Abd El-Basset FZ, Tomoum HY, Tohamy SM, Zaky AA, Mohamed MS, Hakky SM, El Barbary NS, Nassef NM. (2004) Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 45(9):1106-1115.
6. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. (2004) Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62:2051-2057. (Pubitemid 38738220)
7. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. (2002) Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58:1348-1353. (Pubitemid 34507160)
8. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. (2000) Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108:37-43.
9. Fife T, Sirven J. (2005) Antiepileptic drugs and their impact on balance. Aging Health 1:147-155.
10. Genton P. (2005) Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol Scand Suppl 182:26-32.
11. Guo CY, Ronen GM, Atkinson SA. (2001) Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42:1141-1147.
12. Johannessen CU, Johannessen SI. (2003) Valproate: past, present, and future. CNS Drug Rev 9(2):199-216.
13. Kafali G, Erselcan T, Tanzer F. (1999) Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 38:93-98. (Pubitemid 29086791)
14. Kruse R. (1968) [Osteopathies in antiepileptic long-term therapy (preliminary report)]. Monatsschr Kinderheilkd 116:378-381.
15. Li CY, Schaffler MB, Wolde-Semait HT, Hernandez CJ, Jepsen KJ. (2005) Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res 20:2150-2158.
16. Loscher W. (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59.
17. Nissen-Meyer LS, Svalheim S, Tauboll E, Reppe S, Lekva T, Solberg LB, Melhus G, Reinholt FP, Gjerstad L, Jemtland R. (2007) Levetiracetam, phenytoin, and valproate act differently on rat bone mass, Structure, and metabolism. Epilepsia 48:1850-1860. (Pubitemid 47537449)
18. Oner N, Kaya M, Karasalihoglu S, Karaca H, Celtik C, Tutunculer F. (2004) Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 40:470-473. (Pubitemid 39070718)
19. Petty SJ, Paton LM, O'Brien TJ, Makovey J, Erbas B, Sambrook P, Berkovic SF, Wark JD. (2005) Effect of antiepileptic medication on bone mineral measures. Neurology 65:1358-1365.
20. Petty SJ, O'Brien TJ, Wark JD. (2007) Anti-epileptic medication and bone health. Osteoporos Int 18:129-142.
21. Price C, Herman BC, Lufkin T, Goldman HM, Jepsen KJ. (2005) Genetic variation in bone growth patterns defines adult mouse bone fragility. J Bone Miner Res 20:1983-1991.
22. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI. (1999) The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 103(3):588-593. (Pubitemid 29274505)
23. Rieger-Wettengl G, Tutlewski B, Stabrey A, Rauch F, Herkenrath P, Schauseil-Zipf U, Schoenau E. (2001) Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics 108:E107.
24. Robinson PB, Harris M, Harvey W, Papadogeorgakis N. (1982) Reduced bone growth in rats treated with anticonvulsant drugs: a type II pseudohypoparathyroidism? Metab Bone Dis Relat Res 4(4):269-275.
25. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K. (2001) Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57:445-449. (Pubitemid 32757591)
26. Schmidt C, Priemel M, Kohler T, Weusten A, Muller R, Amling M, Eckstein F. (2003) Precision and accuracy of peripheral quantitative computed tomography (pQCT) in the mouse skeleton compared with histology and microcomputed tomography (microCT). J Bone Miner Res 18:1486-1496.
27. Schroeder TM, Westendorf JJ. (2005) Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 20:2254-2263. (Pubitemid 41698788)
28. Senn SM, Kantor S, Leury BJ, Andrikopoulos S, O'Brien TJ, Morris MJ, Proietto J, Wark JD. (2007) In vivo quantification of fat content in mice using the Hologic QDR 4500A densitometer. Obesity Research & Clinical Practice 1:69-77.
29. Sheth RD. (2004) Metabolic concerns associated with antiepileptic medications. Neurology 63:S24-S29.
30. Sims NA, Morris HA, Moore RJ, Durbridge TC. (1996) Increased bone resorption precedes increased bone formation in the ovariectomized rat. Calcif Tissue Int 59:121-127. (Pubitemid 26266277)
31. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R. (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30:18-25. (Pubitemid 34044296)
32. Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E. (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50:2338-2346.
33. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ. (2006) Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab 290: E456-E462.
34. Tommasini SM, Morgan TG, van der Meulen M, Jepsen KJ. (2005) Genetic variation in structure-function relationships for the inbred mouse lumbar vertebral body. J Bone Miner Res 20:817-827.
35. Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y, Tsukahara Y, Miura M, Mayumi M. (2002) Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 44:247-253.
36. Vestergaard P, Rejnmark L, Mosekilde L. (2004) Fracture risk associated with use of antiepileptic drugs. Epilepsia 45:1330-1337. (Pubitemid 39470036)
37. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. (1984) Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 58:1003-1009.
38. Wolden-Hanson T, Gidal BE, Atkinson RL. (1998) Evaluation of a rat model of valproate-induced obesity. Pharmacotherapy 18(5):1075-1081.